Articles tagged with Cancer Medication
A Phase III clinical trial shows that patients with relapsed CLL who achieve complete response with oblimersen combination therapy live significantly longer than those treated with chemotherapy alone. The median survival time for oblimersen-treated patients is estimated to exceed 49 months, whereas it was 35 months for those on F/C alone.
Researchers are studying the safety and effectiveness of African plants used by traditional healers for treating various ailments, including AIDS and respiratory infections. The study aims to uncover the medicinal properties and potential benefits of these plants, with a focus on South Africa's vast botanical diversity.
A study highlights the need for improved patient information and counseling on nuclear medicine procedures, which can trigger radiation alarms in public places. Healthcare professionals, especially those in outpatient facilities, require formal training and standardization of instructions to ensure patient safety.
Researchers from the University of California, San Diego, have identified a protein called LRP1 that may help ease neuropathic pain by blocking the response of glial cells. The study found that administering LRP1 into injured peripheral nerves decreased the level and activity of proinflammatory cytokines, leading to reduced pain.
A series of genes has been identified as protecting cells from the harmful effects of doxorubicin, a commonly used chemotherapeutic agent. The long-term goal is to develop ways to turn these genes off in cancer cells and on in heart cells to prevent or mitigate heart damage.
Researchers re-engineered imatinib to specifically target gastrointestinal stromal tumor and reduce cardiotoxic side effects. The new drug, WBZ-4, was found to be equally effective against gastrointestinal cancer while significantly reducing the risk of heart failure in animal tests.
Male BRCA1 and BRCA2 mutation carriers have a higher risk of developing breast cancer compared to noncarriers. A high carbohydrate diet may also promote prostate tumor growth in mice, while infection with human papillomavirus (HPV) is associated with an increased risk of head and neck cancers but does not further increase the risk when...
A novel computer technique predicts side effects of major pharmaceuticals, including SERMs for breast cancer treatment. The approach shortens drug development and reduces costly recalls by identifying off-target proteins.
Findings from two large clinical trials demonstrate significant improvement in patients with multiple myeloma who received Revlimid, an oral cancer drug, compared to those receiving a placebo. The study showed improved median survival and response rates, offering new hope for patients with this challenging disease.
Researchers found unprecedented survival for patients with multiple myeloma when treated with lenalidomide and dexamethasone, achieving a median survival of nearly three years. The study shows promise for early treatment and has changed official guidelines to add REVLIMID as an initial treatment.
Researchers found that bortezomib selectively inhibits melanoma tumor cells by overactivating the cancer-promoting gene c-MYC, leading to increased production of NOXA and promoting cell death. The study suggests a novel treatment strategy for various types of cancer.
Researchers develop nanoparticles that can be controlled by electromagnetic pulses to release therapeutic drugs directly into tumors, a potential breakthrough in cancer treatment. The system uses heat-sensitive DNA tethers to release drugs, allowing for customizable and targeted delivery.
Researchers at the University of California, San Diego found a strong association between deficiency in UVB exposure and endometrial cancer. Vitamin D3 levels were linked to lower risk of cancers such as breast, colon, kidney, and ovary.
A new model for predicting estrogen receptor-positive breast cancer risk in postmenopausal women performs almost as well as the standard Gail model and could be used to identify high-risk women. Smoking is associated with rectal cancer, while drugs like ZD6126 may cause heart damage due to cardiovascular changes.
A recent clinical trial demonstrated that 50% of patients with active early rheumatoid arthritis achieved clinical remission after one year of treatment with ENBREL plus methotrexate. The study also showed significant improvements in symptoms and joint damage, setting a new standard for earlier treatment of RA.
Researchers developed a novel compound that blocks the breakdown of retinoic acid, derived from vitamin A, and found it to be an effective agent in treating animal models of human prostate cancer. The compound resulted in up to a 50 percent decrease in tumor volume and prevented further tumor growth.
A comprehensive genome analysis of lung cancer cells has identified more than 50 frequent genetic changes, with less than half involving known cancer genes. The study also uncovered a critical gene alteration not previously linked to any form of cancer, shedding light on the disease's biological basis.
A comprehensive analysis of the genomic changes underlying lung cancer has uncovered a critical gene alteration not previously linked to any form of cancer. The study revealed over 50 genomic regions frequently gained or lost in lung adenocarcinoma, with one region pinpointing an important gene that controls lung cell growth.
Researchers found that inositol and IP6 protected human skin cells from UVB radiation damage and increased the potency of radiation therapy against cancer cells. The antioxidants may also offer protection against accidents or incidents involving nuclear material, such as dirty bombs.
Researchers developed a mouse model to predict the loss of orally administered drugs due to CYP3A metabolism. The study found that mice with human CYP3A expression in the intestine had higher docetaxol levels, while those with liver expression showed only slight decreases.
UMMS associate professor JeanMarie Houghton received a Presidential Early Career Award for Scientists and Engineers, recognizing her work on the link between gastric cancers and bone marrow-derived stem cells. Her research aims to understand the progression of events leading to cancer development and develop targeted treatments.
Researchers at Albert Einstein College of Medicine successfully treated cancers by targeting viruses that cause them, slowing tumor growth and even causing tumors to regress. The approach holds promise for preventing cancer by destroying virus-infected cells before they become cancerous.
A retrospective study found that patients taking statin drugs alongside high-dose radiation therapy had a 10% higher chance of being cured of prostate cancer at 10 years after diagnosis. The study also showed reduced rates of cancer spreading to distant parts of the body in men who took statins during radiation treatment.
Researchers are investigating vinflunine as a potential treatment for advanced bladder cancer patients who cannot receive standard cisplatin and gemcitabine chemotherapy due to kidney problems. The Phase II study aims to determine if vinflunine can effectively treat the disease while minimizing side effects.
A phase II trial of axitinib has shown promising activity in patients with cytokine-refractory, metastatic kidney cancer. In the trial, 23 patients had complete or partial responses, with some responses lasting up to 26 months.
Three studies investigate how tumors respond to EGFR inhibitors, revealing the crucial role of BIM protein in triggering apoptosis. The findings suggest that induction of BIM may lead to a new way of treating tumors resistant to these drugs.
The study found that Helicobacter pylori strains inhibit gap junctional intercellular communication in gastric cells, leading to increased cancer risk. The researchers suggest that this mechanism may be a key factor in the development of gastric cancer.
The Yale School of Medicine researchers are studying how cancer cells mend their own chromosomes and DNA after damage caused by radiation and chemotherapy. They hope to create an 'Achilles heel' for cancer cells that would make them more vulnerable to traditional cancer therapies.
A study found that valsartan reduces Alzheimer's disease-like symptoms in mice by lowering brain beta-amyloid protein levels. A new virotherapeutic also shows promise in treating cancer by selectively targeting cancer cells.
Researchers have discovered blood plasma proteins that rise and fall after treatment with antiangiogenic drugs, which may be used as surrogate biomarkers to predict the optimal dose. The study also found molecular changes in normal mice, suggesting that the body's response is not solely tumor-dependent.
Researchers are discovering ways of combining new and existing drugs to fight cancer, broadening the targets of already-approved targeted therapeutics. A combination of CP-751871 and rapamycin has shown a highly effective therapy for xenografts derived from childhood sarcomas.
Researchers will investigate barriers to treating ischemic strokes and explore the effectiveness of patient navigators and imaging studies to address disparities in DC hospitals. The projects aim to improve stroke prevention, diagnosis, and treatment for medically underserved communities.
Researchers have discovered that combining targeted therapies can be more effective than single drugs, particularly when targeting multiple pathways such as the MAPK and PI3-kinase pathways. This approach may help overcome drug resistance and improve treatment outcomes for various types of cancer, including lung and breast cancer.
Researchers present studies on novel insulin-like growth factor receptor enzyme inhibitors and approved drugs in new applications, showing promising results in solid tumors and metastatic renal cancer. Early evidence suggests antitumor activity and potential benefits for patients with advanced hepatocellular carcinoma and metastatic ki...
Researchers have developed new means of screening vast stores of data to find potential therapies for neuroblastoma and other cancers. By targeting cellular molecules along pathways crucial for sustaining cancer cell life, they identified 47 candidates with good potential against neuroblastoma.
A Kaiser Permanente study found that electronic medical records and outreach programs significantly improved osteoporosis diagnosis and management in older women. The study, which analyzed data from 3,588 women aged 67 and older, showed a significant increase in bone density screening and osteoporosis medication after a fracture.
The Institute of Medicine report outlines an action plan to ensure that cancer patients receive necessary psychosocial health services. Key findings include the need to address psychological and social side effects, increasing patient suffering and treatment adherence.
Researchers found that certain existing drugs can target and inhibit the growth of brain tumors by modifying key signaling molecules. The study suggests that these drugs may be repurposed for treatment of brain tumors.
Researchers have developed nanodiamond clusters that efficiently carry and release chemotherapy drugs, sparing healthy cells from toxicity. The material's stability, safety, and high surface area make it a promising alternative to current drug delivery agents.
Researchers have discovered new small molecules that can prevent prostate cancer cells from turning off normal genes by blocking the action of a methyl-CpG binding protein. This breakthrough has significant implications for the development of targeted therapies for prostate and other cancers.
A study of 1,421 cancer patients found no difference in treatment location or wait times between pre- and post-Medicare reimbursement cuts. Patient satisfaction with care remained high, with similar levels of satisfaction reported by patients treated before and after the changes.
Eva Harth's system delivers drugs to specific intracellular compartments, including the brain, and reaches tumors in the lungs, brain, and spinal cord. It also enables delivery of peptides, proteins, DNA, and smaller chemical compounds.
A team of Brown University researchers has made a major breakthrough in understanding the biochemical process of cytokine receptor signal transduction. They found that acetylation, another chemical process, plays a central role in activating interferon receptors and triggering an immune response.
Researchers discovered critical telomere length and chromosomal fusion, offering hope for an early warning test. Telomeres play a crucial role in cell division, and their dysfunction can lead to cancer formation.
A team of scientists discovered that a cell protein plays a crucial role in protecting cancer cells from chemotherapy drugs. Blocking this protein's expression increased sensitivity to chemotherapeutic drugs in lung cancer cells, offering a potential target for improving treatment outcomes.
A new study by UC Irvine scientists suggests that Imatinib can drive cancer into remission in people with chronic myeloid leukemia (CML) if taken over a long enough period of time. The researchers developed a mathematical formula to calculate the optimal treatment duration, which could potentially lead to a cure.
Researchers at UC Irvine find Imatinib can kill cancerous stem cells, potentially curing CML under certain circumstances. A mathematical formula helps determine the optimal treatment duration.
Pertuzumab prolongs survival time for women with Stage 3 ovarian cancer, a Phase II clinical trial found. The experimental drug added weeks to the standard survival period and was well-tolerated by the body.
A study presented at the European Cancer Conference found that axitinib shrank tumours and delayed disease progression in patients with advanced kidney cancer. The drug, which is also being tested in other types of cancer, showed promising results in a group of heavily pre-treated patients.
The experimental drug STA-4783 has been shown to delay cancer progression and prolong patient lives by inducing oxidative stress in cancer cells. In a randomized trial, patients treated with the combination of STA-4783 and chemotherapy lived up to 12 months after diagnosis, compared to 7.8 months for those receiving only chemotherapy.
A study of deceased men found that prostate cancer diagnosis depends more on the biopsied area than sample number, suggesting a new approach to design biopsies. Alternative trial designs and targeting tumor microenvironments may also improve cancer treatment outcomes.
A systematic review of physician awareness found doctors underestimate expensive drugs' costs and overestimate inexpensive ones. Meanwhile, a policy paper reveals drug companies control research, writing, and publication of medical articles, often using medical education and communication companies to promote their interests.
Researchers identified two genes that can predict which breast cancer cells will respond to docetaxel chemotherapy and which will resist it. A simple test for docetaxel resistance could be developed, sparing patients from unnecessary side effects and reducing healthcare costs.
Current studies show promise in reducing malignancies with 5-alpha reductase inhibitors and dietary fat impact on disease development. Other compounds like soy, selenium, and green tea offer additional possibilities for disease prevention.
A study found that heat-shock transcription factor HSF1 enables normal cells to become cancerous by orchestrating proliferation and survival processes. Depriving cancer cells of HSF1 strongly suppresses their growth and survival, offering a potential new approach to fighting cancer.
Gynecomastia, benign enlargement of male breast tissue, affects 40-50% of males at some point in their lives. The condition can be treated with medication or surgery, and awareness is key to correct diagnosis and reassurance for affected men.
A new study used gene chip data to improve treatment outcomes for patients with advanced, incurable cancer. Four out of seven patients showed a better response than expected when their tumor's gene expression was analyzed and used to guide treatment.
A two-year study from the University of Pittsburgh School of Medicine found that women who took a weekly dose of risedronate lost significantly less bone than those who did not take the drug. Risedronate improved bone density and prevented excess bone loss in breast cancer survivors, even among those on aromatase inhibitors.
Researchers at Dana-Farber Cancer Institute have found that many brain tumors and solid tumors require simultaneous inhibition of multiple cell-growth switches to be effective. Combining three or more targeted drugs may provide a cure for these cancers, as individual drugs often yield disappointing results.
A new study shows that tamoxifen, a breast cancer medication, dramatically reduces manic symptoms of bipolar disorder more quickly than many standard medications. Tamoxifen blocks an enzyme called protein kinase C, which is thought to be over-active during the manic phase.